Gemcitabine Hydrochloride Injection

• Type: Anticancer medication

• Drug Class: Antimetabolite / Pyrimidine analog

• Form: Lyophilized powder or solution for intravenous (IV) infusion

How It Works

• Gemcitabine is taken up by cells and converted into active metabolites.

• These metabolites:

  • Incorporate into DNA, causing chain termination

  • Inhibit ribonucleotide reductase, reducing DNA building blocks

• Together, these actions block DNA synthesis and trigger cell death, particularly in rapidly dividing cancer cells.

Common Uses

Gemcitabine injection is widely used in the treatment of:

• Pancreatic cancer (often first-line therapy)

• Non-small cell lung cancer (NSCLC) – in combination with cisplatin

• Bladder cancer – often used with cisplatin

• Breast cancer – in combination with paclitaxel for metastatic disease

• Ovarian cancer – as part of combination regimens

• Biliary tract cancers (cholangiocarcinoma, gallbladder cancer)

Advantages

• Well tolerated compared to some other chemotherapies

• Can be combined with other agents (cisplatin, carboplatin, paclitaxel) for synergistic effect

• Effective against a wide variety of solid tumors

Possible Side Effects

Common:

• Mild to moderate bone marrow suppression (neutropenia, anemia, thrombocytopenia)

• Flu-like symptoms (fever, fatigue, muscle aches)

• Nausea, vomiting

• Mild rash or skin reactions

Less Common but Serious:

• Severe myelosuppression (low blood counts)

• Liver enzyme elevation

• Kidney problems (rare but possible)

• Pulmonary toxicity (rare interstitial pneumonitis or pulmonary edema)

• Capillary leak syndrome or hemolytic uremic syndrome (very rare but serious)

Precautions

• Blood counts should be monitored before each cycle

• Dose adjustment may be necessary in liver or kidney dysfunction

• Use with caution in patients with pre-existing lung disease

• Monitor for signs of infection due to bone marrow suppression